BACKGROUND AND OBJECTIVE: The successful use of differentiating treatment for
patients with acute promyelocytic leukemia (APL) suggests that other acute myeloid …

Recent progress in the molecular genetics of acute myeloid leukemia (AML) has shown this
disease to be more heterogeneous than previously realized. Recurrent cytogenetic and …

In recent years, research in genomics has resulted in the rapid uncovering of the molecular
pathogenesis of acute myeloid leukemia (AML). The identification of the genetic …

The heterogeneity of acute myeloid leukemia (AML) results from a complex network of
cytogenetic aberrations and molecular mutations. These genetic markers are the basis for …

The list of acquired mutations with clinical value in AML is growing. Clinical implementation
of this multitude of markers will require integrated approaches and selection of markers to …

Acute myeloid leukemia (AML) is a genetically heterogeneous clonal disorder characterized
by the accumulation of acquired somatic genetic alterations in hematopoietic progenitor …

The therapeutic approach to the patient with acute myeloid leukemia (AML) currently
evolves toward new frontiers. This is particularly apparent from the entree of high-throughput …

Intensification of induction and postremission chemotherapies has resulted in a steady
improvement in outcomes for adults with acute myeloid leukemia (AML) over the past two …

Although standard therapy for AML has been relatively constant over the past 2 decades,
this may be changing with enhanced technologies allowing for the classification of acute …

Genetic mutations in acute myeloid leukemia that influence c... : Current Opinion in Hematology
Genetic mutations in acute myeloid leukemia that influence clinical decisions : Current Opinion …